Researchers conducted a Phase 3 clinical trial to see if the medication nemolizumab could help patients keep their skin clear over time. The study included 507 people, including both adolescents and adults, who had moderate to severe atopic dermatitis and were already showing improvement after 16 weeks of treatment.
The study compared two different dosing schedules for nemolizumab against a group that stopped taking the medication while continuing their usual topical creams. Patients receiving nemolizumab every four or eight weeks showed significantly higher rates of maintaining clear skin and reduced symptoms compared to those who stopped the drug. Specifically, more than 60% of patients on the nemolizumab plans maintained success at week 48.
The trial also found that nemolizumab helped manage itching and improved sleep for those with severe skin issues. Safety results showed no major differences in side effects between the different dosing groups. Because this was a large, controlled study, it provides strong evidence that nemolizumab can help maintain skin health over several months.
